Rexin-G is under clinical development by Epeius Biotechnologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rexin-G’s likelihood of approval (LoA) and phase transition for Osteosarcoma took place on 29 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rexin-G Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rexin-G overview

Rexin-G is under development for the treatment of chondrosarcoma, chordoma, sarcoma, pancreatic cancer, osteosarcoma, soft tissue sarcoma and Coronavirus Disease 2019 (COVID-19) associated with pneumonia and acute respiratory distres syndrome. It was under development for the treatments of advanced metastatic breast cancer and metastatic cancer. Rexin-G is a sophisticated gene delivery vehicle (vector). It is a tumor-targeted nanoparticle that is programmed to deliver a tumor-killing designer gene precisely where it is needed most. It is a genetic medicine. It is highly active against a broad spectrum of chemo-resistant tumor types. It causes tumor shrinkage in patients suffering from metastatic cancer, without causing dose-limiting toxicity or organ damage. It is a biological agent directed towards tumors that have spread throughout the body. The drug candidate is administered intravenously. The combination of Rexin-G and Reximmune-C was under investigation for the treatment of cancer.

Epeius Biotechnologies overview

Epeius Biotechnologies (Epeius) is a biopharmaceutical company, based in the US. The company operates through drug manufacturing and delivery. It develops therapeutic and drug delivery system for the treatment of cancer. The company’s pipeline includes Rexin-G, a tumor targeted injectable genetic medicine for the treatment of primary and metastatic cancer and Reximmune-C a cancer vaccine. Its targeted drug Delivery System works by injecting stealth nanoparticles directly into a vein so that the therapeutic genes can be delivered to selected cancerous lesions without affecting normal cells and healthy tissues. The company was incorporated in the year, 2000. Epeius is headquartered in San Marino, California, the US.

Quick View Rexin-G LOA Data

Report Segments
  • Innovator
Drug Name
  • Rexin-G
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.